Literature DB >> 18386235

Human tissue transglutaminase antibody screening by immunochromatographic line immunoassay for early diagnosis of celiac disease in Turkish children.

Fulya G Demirçeken1, Aydan Kansu, Zarife Kuloğlu, Nurten Girgin, Haluk Güriz, Arzu Ensari.   

Abstract

BACKGROUND/AIMS: Celiac disease has a large prevalence worldwide. There are a limited number of comparable epidemiological data for celiac disease in Turkey. The aim of this preliminary study was to determine the prevalence of celiac disease in a sample of 1000 Turkish children by a novel, simple, and visual one-step immunoassay screening test.
METHODS: This prospective study consisted of 1000 serum samples from apparently healthy children and children with disorders other than celiac disease aged between 2-18 years who presented as outpatients at Ankara University, Faculty of Medicine, Department of Pediatrics. Sera were tested for IgA-class antibodies against human tissue transglutaminase and gliadin by rapid immunochromatographic line immunoassay. Endomysial antibody IgA against human tissue transglutaminase and AGA IgA/IgG were also tested by ELISA as a second step when the result of the screening test was positive. Small bowel biopsy was recommended to all the children with positive anti-tissue transglutaminase and/or endomysial antibody results.
RESULTS: Ten of the 1000 individuals (1%) had positive antibody screening test to human tissue transglutaminase. All tissue transglutaminase-positive samples revealed good correlation with endomysial antibody by ELISA method. Subsequently small bowel biopsy was performed in all serology-positive cases. Biopsy results confirmed a diagnosis of celiac disease in nine cases. The prevalence of biopsy- proven celiac disease was 1:111 (0.9%).
CONCLUSIONS: Determination of anti-tissue transglutaminase antibodies by simple visual system for celiac disease appeared to be as reliable as the ELISA system. It is easy to perform and interpret, cost-effective, and rapid, as pointed out in other previous studies, as a screening test in large population-based studies. The prevalence of celiac disease in the overall sample of Turkish children (1:111 or 0.9%) in this preliminary study is similar to that reported in European and Middle Eastern countries and the United States.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386235

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  5 in total

1.  Silent neurological involvement in biopsy-defined coeliac patients.

Authors:  Basar Bilgic; Demet Aygun; Ali Bilgin Arslan; Ali Bayram; Filiz Akyuz; Serra Sencer; Hasmet A Hanagasi
Journal:  Neurol Sci       Date:  2013-04-25       Impact factor: 3.307

2.  Prevalence of celiac disease in Turkish children with autoimmune thyroiditis.

Authors:  Sinan Sari; Ediz Yesilkaya; Odul Egritas; Aysun Bideci; Buket Dalgic
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

3.  Turkish Validity-Reliability Study of the Celiac Disease-Specific Pediatric Quality of Life Scale.

Authors:  Cemal Koçak; Semih Sandal; Meltem Çöl; Aydan Kansu Tanca; Zarife Kuloğlu; Ceyda Tuna Kırsaçlıoğlu
Journal:  Turk J Gastroenterol       Date:  2022-03       Impact factor: 1.555

4.  A point-of-care test for facing the burden of undiagnosed celiac disease in the Mediterranean area: a pragmatic design study.

Authors:  Stefano Costa; Luca Astarita; Mongi Ben-Hariz; Giovanni Currò; Jernej Dolinsek; Aydan Kansu; Giuseppe Magazzu'; Stefania Marvaso; Dusanka Micetic-Turku; Salvatore Pellegrino; Giuseppe Primavera; Pasqualino Rossi; Andrea Smarrazzo; Francesca Tucci; Carmela Arcidiaco; Luigi Greco
Journal:  BMC Gastroenterol       Date:  2014-12-18       Impact factor: 3.067

5.  Investigation of celiac disease followed by immune thrombocytopenic purpura diagnosis in patients and comparison with literature.

Authors:  Hakan Sarbay; Halil Kocamaz; Mehmet Akin; Bayram Ozhan
Journal:  North Clin Istanb       Date:  2017-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.